JonesResearch says Larimar Therapeutics (LRMR) announced the application submission for nomlabofusp in Friedreich’s Ataxia is targeted for Q2 of 2026, which is pushed back from year-end 2025 based on FDA feedback on safety database requirements. The firm expects the stock could trade down initially given the delay, but still sees the news “as a step in the right direction.” Larimar’s biggest overhang was regulatory uncertainty, specifically with regard to accelerated approval, the analyst tells investors in a research note. Having written recommendations from the FDA should alleviate some of these concerns, contends JonesResearch. It keeps a Buy rating on the shares with a $14 price target The stock in premarket trading is down 6% to $2.43.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.